Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14274 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Hafsah Chalchal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ontario, Ottawa, Canada. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Unrelated Donors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Anti‐thymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis is widely used for mismatched unrelated donor allogeneic hematopoietic cell transplantation (HCT) although optimal dose remains unclear. Although recent literature suggested improved outcomes with PTCy‐based regimens when compared to ATG‐based regimens these studies used doses of ATG ≥5 mg/kg. Thus, we analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower‐dose ATG‐based regimens at our center.
Methods
We retrospectively analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower dose ATG‐based regimens for all adults undergoing allogeneic HCT at The Ottawa Hospital from 2015 to 2022. Data regarding demographics, conditioning regimen, dose of ATG, rates of GVHD, duration of remission, and survival, were collected and analyzed.
Results
Seventy‐seven ( n = 77) patients (males 62.3%; median age 50 years) underwent allogeneic HCT from MMUD. Majority(81%; n = 63) received 2.5 mg/kg of rabbit ATG and remaining 18.2% ( n = 14) received 4.5 mg/kg. Grade II‐IV acute GVHD occurred in 24.7% ( n = 19) while any chronic GVHD occurred in 32.5% ( n = 25) patients. After a median follow‐up of 21 months, relapse occurred in 28.6% of patients. Two‐year OS, GRFS, CIR, and NRM were 60.6%, 45.3%, 16.9%, and 18.2% respectively. Dose of ATG (2.5 mg/kg vs. 4.5 mg/kg) was not associated with outcomes in either univariate or multivariate analyses.
Conclusions
When compared to published studies using ATG doses ≥5 mg/kg, GVHD prophylaxis using lower dose ATG may potentially lead to improved outcomes in patients undergoing MMUD allogeneic HCT. Further studies are needed to directly compare lower dose ATG to PTCy‐based regimens to determine ideal GVHD prophylaxis for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ontario, Ottawa, Canada.
Zitieren
APA
Chalchal, H., Dhir, V., Masurekar, A., Atkins, H., Bredeson, C., Kennah, M., Kekre, N., Allan, D., & Vasudevan Nampoothiri, R. (2024). Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14274
Vancouver
Chalchal H, Dhir V, Masurekar A, Atkins H, Bredeson C, Kennah M, et al. Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. European Journal of Haematology. 2024. doi:10.1111/ejh.14274
BibTeX
@article{Chalchal2024,
author = {Chalchal, Hafsah and Dhir, Vinita and Masurekar, Ashish and Atkins, Harold and Bredeson, Christopher and Kennah, Michael and Kekre, Natasha and Allan, David and Vasudevan Nampoothiri, Ram},
title = {Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14274}
}
EUVIMED